Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
623 Leser
Artikel bewerten:
(2)

ENERGISME: E-Health: the Universities of Nice Côte d'Azur and Rouen choose Loamics and its partner MyDataModels to collect, process and analyse medical data and improve patient journeys.

DJ ENERGISME: E-Health: the Universities of Nice Côte d'Azur and Rouen choose Loamics and its partner MyDataModels to collect, process and analyse medical data and improve patient journeys.

ENERGISME ENERGISME: E-Health: the Universities of Nice Côte d'Azur and Rouen choose Loamics and its partner MyDataModels to collect, process and analyse medical data and improve patient journeys. 17-Feb-2022 / 17:52 CET/CEST Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

E-Health: the Universities of Nice Côte d'Azur and Rouen choose Loamics and its partner MyDataModels to collect, process and analyse medical data and improve patient journeys

The teaching and general research departments of the Universities of Côte d'Azur and Rouen, in partnership with the DERMG (Department of Teaching and Research in General Medicine), use Loamics and MyDataModels for the analysis and processing of medical data. This initiative is the first stage in the PRIMEGE (Regional General Medicine Information Platform) project, which aims to collect anonymised data directly from the consultation software, without any effort on the part of the doctor, in order to build a database for research and evaluation of practices in general medicine.

It is currently very difficult to consolidate and analyse medical data in a global and relevant way since it comes from various software applications, which do not communicate with each other and only partially with the public health service. The non-interoperability of systems and the diversity, volume, security, governance and personal nature of medical data are all major challenges to be met in order to obtain the quality data that is an essential prerequisite for reliable analyses.

That is why the two Universities of Côte d'Azur and Rouen are using the solution offered by Loamics and MyDataModels. Loamics is a software publisher and has developed a PaaS software suite to address data issues. The Loamics platform is a very powerful infrastructure capable of processing huge masses of varying data types, continuously or in real time, through a fully automated, industrialised process. The system is interoperable, able to connect to any data source and handle any transmission protocol, to make the data more reliable and uniform. Once the intelligence of the data has been revealed, it is ready to be submitted to the artificial intelligence and predictive modelling platform developed by MyDataModels.

This project is being rolled out on a private cloud certified for its compliance with the French government's HDS (Health Data Hosting) standard, enabling it to respond to all security issues.

David Darmon, a doctor, Director of the DERMG and Professor at the University of Côte d'Azur, says, "Today, in France, we are not exploiting the potential of medical data. We started by launching a pilot with Loamics which proved to be very conclusive and its results made us decide to entrust the project to Loamics and MyDataModels. Our ambition is simple, to enhance the data at our disposal to improve diagnosis, accelerate research and ensure personal patient care, while ensuring the maximum security of this data which we know to be sensitive."

Stéphane Bollon, CEO of Loamics, adds, "Thank you to David Darmon, Matthieu Schuers (1) and Stefan Darmoni (2) for their confidence and for their ambition. Loamics is a solution that cuts across all business sectors. In the healthcare field, one of its differentiating advantages lies in our ability to manage metadata, which makes it very easy to anonymise data and overcome security challenges. We offer a solution that is unique on the market and we are confident in our ability to move forward with companies that have tested our solution and are unanimous on the value provided. 1. Matthew Schuers, lecturer at the University of Rouen and General Practitioner 2. Stephane Darmoni, Professor of Medicine at Rouen University Hospital

ABOUT ENERGISME

ENERGISME has developed a SaaS software solution, N'gage, aimed at accelerating the energy performance of companies (energy service providers, energy suppliers and distributors, industrialists and property managers) thanks to data intelligence, as well as a PaaS platform, Loamics, dedicated to real-time processing of massive and heterogeneous data. With the decisive technological and operational advantages of its platform, ENERGISME already has more than 170 major customers. The solution is also marketed by leading players under white label. ENERGISME (ISIN Code: FR0013399359/ Mnemonic: ALNRG) has been listed since July 2020 on the Euronext Growth market.

ENERGISME is a company eligible for the PEA-PME, and is also qualified as a BPI Innovative Company and BPI Excellence.

More information: https://energisme.com/investisseurs/

CONTACTS

ENERGISME           Press           Investors 
Sandrine Chauvin       Jennifer Jullia      Stéphane Ruiz 
 
investisseurs@energisme.com  jjullia@actifin.fr     sruiz@actifin.fr 
Tel. +33 (1) 81 89 33 90   Tel. +33 (1) 56 88 11 19  Tel. +33 (1) 56 88 11 26 

-----------------------------------------------------------------------------------------------------------------------

Regulatory filing PDF file File: Energisme - E-Health UK

1282723 17-Feb-2022 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1282723&application_name=news

(END) Dow Jones Newswires

February 17, 2022 11:52 ET (16:52 GMT)

© 2022 Dow Jones News
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.